Iovance Biotherapeutics

IPO

Iovance Biotherapeutics is a biotech company in San Carlos, United States, founded in 2007. It has raised $100.0M across 2 rounds, most recently a $100.0M Series B in June 2016.

Investigating TIL Therapy for Cancer

Employees
501–1000
Founded
2007
Business Model
B2B
Total Funding
$100.0M
Last Round
$100.0M Series BJun 2016
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds for this company. The full record is or through the API.

About

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. The company is pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance is committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer. Its product lineup includes Amtagvi and Proleukin, and the company operates the Iovance Cell Therapy Center for manufacturing.

Summary

It lists 501–1000 employees. It has raised $100.0M in total across 2 rounds, most recently a $100.0M Series B round in Jun 2016.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
Secondary MarketSecondary MarketAug 2025

Sign up to see all 7 events

Funding: Corporate Round through Series B. Amounts, valuations, and investors where available.

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Iovance Biotherapeutics on Indexed.vc
<a href="https://indexed.vc/companies/iovance-biotherapeutics"><img src="https://indexed.vc/api/badge/company/iovance-biotherapeutics" alt="Iovance Biotherapeutics on Indexed.vc" width="260" height="76" /></a>